What's Happening?
Roche has decided to discontinue the development of acmopatide, an investigational obesity treatment from its acquisition of Carmot Therapeutics, to prioritize enicepatide, another promising candidate. Acmopatide was being developed for type 1 diabetes
with obesity but will no longer be pursued as Roche shifts focus to enicepatide, a dual agonist of the GLP-1 and GIP receptors. Enicepatide has shown significant weight reduction in Phase 2 trials, with potential best-in-class weight loss effects. Roche plans a broad Phase 3 program for enicepatide, targeting weight loss, type 2 diabetes, and cardiovascular outcomes.
Why It's Important?
The strategic shift by Roche underscores the competitive landscape in the obesity treatment market, where effective weight loss solutions are highly sought after. Enicepatide's promising results position it as a potential leader in the field, offering significant benefits for patients struggling with obesity and related conditions. This move reflects Roche's focus on maximizing the impact of its portfolio by advancing the most promising candidates, which could lead to significant advancements in obesity management and related health outcomes.
What's Next?
Roche plans to advance enicepatide into a comprehensive Phase 3 program, with studies focusing on weight loss, type 2 diabetes, and cardiovascular outcomes. A regulatory submission for obesity treatment could occur as early as 2028. The company will also continue to develop other assets in its obesity portfolio, including the Zealand Pharma-partnered amylin asset petrelintide, which is expected to enter late-stage development following further trial results.
